Learn more

MOLECULAR PARTNERS AG

Overview
  • Total Patents
    131
  • GoodIP Patent Rank
    23,698
  • Filing trend
    ⇩ 81.0%
About

MOLECULAR PARTNERS AG has a total of 131 patent applications. It decreased the IP activity by 81.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and chemical engineering are ROCHE GLYCART AG, TEVA PHARMACEUTICALS AUSTRALIA PTY LTD and ABBVIE BIOTHERAPEUTICS INC.

Patent filings per year

Chart showing MOLECULAR PARTNERS AGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Binz Hans Kaspar 66
#2 Forrer Patrik 46
#3 Stumpp Michael Tobias 32
#4 Dolado Ignacio 32
#5 Phillips Douglas 29
#6 Merz Frieder W 28
#7 Steiner Daniel 24
#8 Sonderegger Ivo 24
#9 Gulotti-Georgieva Maya 23
#10 Fiedler Ulrike 22

Latest patents

Publication Filing date Title
WO2020245173A1 Recombinant fap binding proteins and their use
UY38739A MULTI-SPECIFIC PROTEINS
WO2020245175A1 Recombinant 4-1bb binding proteins and their use
WO2020245171A1 Designed ankyrin repeat domain with improved stability
KR20190050802A Recombinant binding proteins and uses thereof
WO2016156596A1 Designed ankyrin repeat domains with binding specificity for serum albumin
AU2014243418A1 Modified binding proteins inhibiting the VEGF-A receptor interaction
US2016251404A1 Designed ankyrin repeat proteins binding to hepatocyte growth factor
AU2013283296A1 Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 Binding proteins comprising at least two binding domains against HER2.
CN103403024A Improved N-terminal capping modules for designed ankyrin repeat proteins
AR081361A1 MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
MX359570B Binding proteins inhibiting the vegf-a receptor interaction.